Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The response to PAK1 inhibitor IPA3 distinguishes between cancer cells with mutations in BRAF and Ras oncogenes.

Oncotarget - 1 Jul 2012

Singhal Ruchi, Kandel Eugene S

Abstract excerpt

While new drugs aimed at BRAF-mutated cancers are entering clinical practice, cells and tumors with activating Ras mutations are relatively resistant to those and quite a few other anti-cancer agents. This inspires the effort to reverse this resistance or to uncover new vulnerabilities in such resistant cancers. IPA3 has been originally identified as a small molecule inhibitor of p21-activated protein kinase 1...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Colonic Neoplasms
Share to BRAF gene
Share to KRAS gene

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Genes, ras

Share to Melanoma

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Source

Open in PubMed Open full text

Identifiers

PMID: 22869096
DOI: 10.18632/oncotarget.587
PMCID: PMC3443253

Genes

PAK1
BRAF
NRAS
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The response to PAK1 inhibitor IPA3 distinguishes between cancer cells with mutations in BRAF and Ras oncogenes.PMID 22869096Read ↗

P21‐activated kinase 1 regulates resistance to BRAF inhibition in human cancer cellsSemantic proximity Read ↗

Therapeutic Potential of Targeting PAK SignalingSemantic proximity Read ↗

Dissecting mechanisms of resistance to targeted drug combination therapy in human colorectal cancerSemantic proximity Read ↗

PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas.Semantic proximity Read ↗

Molecular Pathways: Targeting P21-Activated Kinase 1 Signaling in Cancer—Opportunities, Challenges, and LimitationsSemantic proximity Read ↗

Dual blockade of the lipid kinase PIP4Ks and mitotic pathways leads to cancer-selective lethalitySemantic proximity Read ↗

Development and utility of a PAK1-selective degraderSemantic proximity Read ↗

Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance.Semantic proximity Read ↗

p21-Activated Kinase 1 Is Required for Efficient Tumor Formation and Progression in a Ras-Mediated Skin Cancer ModelSemantic proximity Read ↗

PAK and PI3K pathway activation confers resistance to KRASG12C inhibitor sotorasib.Semantic proximity Read ↗

PAK signaling in cancerSemantic proximity Read ↗

Herbal Therapeutics that Block the Oncogenic Kinase PAK1: A Practical Approach towards PAK1-dependent Diseases and LongevitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.